Evidence map›Paper›PMID 36142780›Full record

ArticleInternational journal of molecular sciences2022

Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis.

Maciej Dulewicz, Agnieszka Kulczyńska-Przybik, Renata Borawska, Agnieszka Słowik, Barbara Mroczko

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maciej DulewiczDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.ORCID 0000-0002-7149-017X
Agnieszka Kulczyńska-PrzybikDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.
Renata BorawskaDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.
Agnieszka SłowikDepartment of Neurology, Jagiellonian University, 30-688 Kraków, Poland.
Barbara MroczkoDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.ORCID 0000-0002-4075-8479
Medical University of Białystok · PLJagiellonian University · PL

Funding

Medical University of Bialystok SUB/1/DN/22/002/1198Project No. POWR.03.02.00-00-I051/16 from the European Union funds, POWER 2014-2020 01/IMSD/G/2021
6 · The paper itself

Abstract

Synaptic loss and dysfunction are one of the earliest signs of neurodegeneration associated with cognitive decline in Alzheimer's disease (AD) and other neurodegenerative diseases. This study aimed to assess the relationships between biological processes of the synaptic pathology underlying AD, molecular functions, and dynamics of the change concentrations of selected proteins reflecting synaptic and axonal pathology in dementia stages. Neurogranin (Ng), neuronal pentraxin receptor (NPTXR), and Visinin-like protein 1 (VILIP1) concentrations were measured in the cerebrospinal fluid (CSF) of MCI, AD, and non-demented controls (CTRL) using quantitative immunological methods. Gene ontology (GO) enrichment analysis was used for the functional analysis of tested proteins. The CSF Aβ42/Ng ratio was significantly different between all the compared groups. The CSF NPTXR/Ng ratio was significantly different between MCI compared to CTRL and AD compared to CTRL. The GO enrichment analysis revealed that two terms (the Biological Process (BP) and Cellular Component (CC) levels) are significantly enriched for NPTXR and Ng but not for VILIP1. Both Ng and NPTXR concentrations in CSF are promising synaptic dysfunction biomarkers for the early diagnosis of the disease. Moreover, both proteins are biochemically associated with classical biomarkers and VILIP-1. Mapping shared molecular and biological functions for the tested proteins by GO enrichment analysis may be beneficial in screening and setting new research targets.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersComputational BiologyHumansNeurocalcinNeurograninPeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersNeurocalcinNeurograninPeptide Fragmentstau ProteinsCSF synaptic biomarkersneurograninneuronal pentraxin receptorVisinin-like protein 1

Identifiers

PMID36142780
PMCPMC9502777
OpenAlexW4296354075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.